Cover Image
市場調查報告書

尿失禁:開發中產品分析

Urinary Incontinence - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232798
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
尿失禁:開發中產品分析 Urinary Incontinence - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 66 Pages
簡介

尿失禁是由於膀胱失去控制造成的狀態。尿失禁的症狀有緊張性尿失禁,皮疹和其他皮膚疾病,高齡化,過重,抽煙,腎臟疾病等是可能發病的要素。主要尿失禁治療藥有抗膽鹼促效劑,局部雌激素等。

本報告提供尿失禁治療藥的開發趨勢調查,提供您開發平台各階段的產品概要,主要企業藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

尿失禁概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

尿失禁:企業開發中的治療藥

尿失禁:大學/機關研究中的治療藥

尿失禁:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

尿失禁:企業開發中的產品

尿失禁:大學/機關研究中的產品

尿失禁治療藥的開發企業

  • Allergan Plc
  • Astellas Pharma Inc.
  • Celogos
  • Cook MyoSite Incorporated
  • Evotec AG
  • FemmePharma Global Healthcare, Inc.
  • Innovacell Biotechnologie AG
  • TheraVida, Inc.

尿失禁:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (mirabegron + solifenacin succinate)
  • ASP-2205
  • ASP-5633
  • Cell Therapy for Urinary Incontinence
  • ICES-13
  • oxybutynin hydrochloride
  • Prof-003
  • RCD-1
  • senrebotase
  • Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence
  • Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases
  • THVD-201
  • THVD-202

尿失禁:最近的開發平台趨勢

尿失禁:暫停中的計劃

尿失禁:開發中止的產品

尿失禁:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8978IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Urinary Incontinence - Overview
  • Urinary Incontinence - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Urinary Incontinence - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Urinary Incontinence - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • Celogos SA
    • Cook MyoSite Inc
    • FemmePharma Global Healthcare Inc
    • GTx Inc
    • Innovacell Biotechnologie AG
    • Ipsen SA
    • Outpost Medicine Ltd
    • Pfizer Inc
    • Taiho Pharmaceutical Co Ltd
    • Takeda Pharmaceutical Company Ltd
  • Urinary Incontinence - Drug Profiles
    • (mirabegron + solifenacin succinate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abobotulinumtoxina - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Urinary Incontinence - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enobosarm - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gtx-027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICES-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OP-233 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxybutynin chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Prof-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RCD-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAS-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Urinary Incontinence - Dormant Projects
  • Urinary Incontinence - Discontinued Products
  • Urinary Incontinence - Product Development Milestones
    • Featured News & Press Releases
      • Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
      • Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
      • Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting
      • Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence
      • Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence
      • May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
      • Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
      • Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
      • Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
      • Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
      • Aug 30, 2011: Innovacell passes a further milestone
      • Feb 22, 2011: Innovacell makes further progress on product development
      • Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence
      • Oct 31, 2008: Fesoterodine Approved in the U.S
      • Feb 28, 2007: HRA Pharma Invest An Additional Euro 2.5 M In Cell Therapy Through Its Subsidiary Celogos
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Urinary Incontinence, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Urinary Incontinence - Pipeline by Astellas Pharma Inc, H1 2017
  • Urinary Incontinence - Pipeline by Celogos SA, H1 2017
  • Urinary Incontinence - Pipeline by Cook MyoSite Inc, H1 2017
  • Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H1 2017
  • Urinary Incontinence - Pipeline by GTx Inc, H1 2017
  • Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2017
  • Urinary Incontinence - Pipeline by Ipsen SA, H1 2017
  • Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H1 2017
  • Urinary Incontinence - Pipeline by Pfizer Inc, H1 2017
  • Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Urinary Incontinence - Dormant Projects, H1 2017
  • Urinary Incontinence - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Urinary Incontinence - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Urinary Incontinence, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top